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Abstract
The CDKN2A/ARF locus encompasses overlapping tumor suppressor genes p16(INK4A) and p14(ARF), which are frequently
co-deleted in human malignant mesothelioma (MM). The importance of p16(INK4A) loss in human cancer is well established,
but the relative significance of p14(ARF) loss has been debated. The tumor predisposition of mice singly deficient for either
Ink4a or Arf, due to targeting of exons 1a or 1b, respectively, supports the idea that both play significant and nonredundant
roles in suppressing spontaneous tumors. To further test this notion, we exposed Ink4a(+/2) and Arf(+/2) mice to asbestos,
the major cause of MM. Asbestos-treated Ink4a(+/2) and Arf(+/2) mice showed increased incidence and shorter latency of
MM relative to wild-type littermates. MMs from Ink4a(+/2) mice exhibited biallelic inactivation of Ink4a, loss of Arf or p53
expression and frequent loss of p15(Ink4b). In contrast, MMs from Arf(+/2) mice exhibited loss of Arf expression, but did not
require loss of Ink4a or Ink4b. Mice doubly deficient for Ink4a and Arf, due to deletion of Cdkn2a/Arf exon 2, showed
accelerated asbestos-induced MM formation relative to mice deficient for Ink4a or Arf alone, and MMs exhibited biallelic loss
of both tumor suppressor genes. The tumor suppressor function of Arf in MM was p53-independent, since MMs with loss of
Arf retained functional p53. Collectively, these in vivo data indicate that both CDKN2A/ARF gene products suppress asbestos
carcinogenicity. Furthermore, while inactivation of Arf appears to be crucial for MM pathogenesis, the inactivation of both
p16(Ink4a) and p19(Arf) cooperate to accelerate asbestos-induced tumorigenesis.
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Introduction
CDKN2A/ARF is among the most commonly mutated loci in
human cancer, encoding two different tumor suppressors translated
from alternatively spliced mRNAs. p16(INK4A) is composed of exons
1a, 2 and 3, and is designated here as INK4A (inhibitor of cyclin
dependent kinase 4). Human p14(ARF) is encoded by exon 1b and
alternate reading frames of CDKN2A/ARF exons 2 and 3, herein
referred to as ARF (alternate reading frame). Knockout mice with
targeted deletion of specific Cdkn2A/Arf exons have disrupted
p16Ink4a, p19Arf or both genes [1,2,3,4] and develop a different
spectrum of spontaneous tumors, although not malignant mesothe-
liomas (MMs). A differential impact of heterozygous loss of Ink4a or
Arf to the induction of MM by asbestos has not been previously
addressed. The studies presented here provide genetic evidence for
the significance of Ink4a and Arf alterations in MM by directly
comparing susceptibility to tumor induction by asbestos in Ink4a-
deficient, Arf-deficient and doubly heterozygous Ink4a;Arf mice in a
common genetic background. The enhanced tumor susceptibility of
mice singly deficient for either p16(Ink4a) or p19(Arf) supports the
view that both play significant and nonredundant roles in suppressing
malignant transformation. The fact that mice deficient for both
tumor suppressors have accelerated tumor development indicates
that inactivation of both p16(Ink4a) and p19(Arf) cooperate to
promote asbestos carcinogenicity.
Results
Using a genetic approach, we assessed the relative contribution
of Ink4a and Arf deficiency to induction of asbestos-induced tumor
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Ink4a(+/2) and Arf(+/2) mice relative to wild-type littermates
(Fig. 1, Supporting File S1). Mice doubly deficient for Ink4a;Arf
had accelerated asbestos-induced MMs relative to mice deficient
for Ink4a or Arf alone. As in prior studies [5,6,7], MM did not
develop in TiO2-treated mice (Supporting File S1). Median
latency for MM detection after initial asbestos exposure was
29.6 weeks for Ink4a;Arf(+/2), 34.6 weeks for Ink4a(+/2), 38.0
weeks for Arf(+/2), and 49.4 weeks for wild-type mice. Ink4a-, Arf-
and Ink4a;Arf-deficient mice had decreased survival compared to
wild-type mice (Fig. 1). Tumor latency for Ink4a- and Arf-deficient
mice was not significantly different, whereas latency was decreased
in Ink4a;Arf-deficient mice (p,0.0001).
Sarcomatoid MMs were prevalent in all asbestos-treated mice
(Fig. 2), although biphasic and epithelial morphology were
occasionally observed. MMs frequently presented with ascites,
occasional spheroids, and diffuse peritoneal seeding of the serosal
lining. Most tumors in wild-type mice were early-stage MMs,
whereas tumors in Ink4a(+/2), Arf(+/2), and Ink4a;Arf(+/2) mice
generally were more advanced. Extensive disease was most evident
in doubly heterozygous mice. In a few cases, diagnosis was difficult
because MMs may arise anywhere in the abdominal cavity and
may not be obvious in the sampled tissues. Thus, where possible,
tumor cells from ascites or peritoneal lavage were tested with
markers to verify MM (Supporting File S1).
Using early passage (#6) MM cells, we found biallelic in-
factivation of the predisposing tumor suppressor gene in all MMs
tested (Fig. 3A). In most (4 of 5 tested) MMs from Ink4a(+/2) mice,
there also was loss of Arf and p15(Ink4b), the latter located near the
Cdkn2a/Arf locus. Tumor #200, from an Ink4a(+/2) mouse,
retained expression of Arf but did not express p53 protein.
Interestingly, in MM cells with loss of Arf, the p53 pathway
appeared to remain functional intact based on their response to
DNA damage with etoposide (100 mM) or UV irradiation (80 J/m
2)
(Fig. 3C).
MMs from Arf(+/2) mice consistently exhibited loss of Arf
protein. In 4 of 5 samples tested, the mutant Arf allele was
retained, as determined by RT-PCR (Supplemental Fig. S2);
insertion of the neo-selectable marker used in the Arf targeting
strategy results in a stop codon and no Arf protein expression
(Fig. 3). Arf(+/2) mice showed loss of Ink4a expression in 3 of 6
MM cultures, whereas p15(Ink4b) was retained in 5 of 6
cultures (Fig. 3). Similarly, inactivation of Ink4a and p15(Ink4b)
were not required for MM formation in a C57Bl/6 Arf(+/2)
model [6].
MMs from Ink4a;Arf doubly heterozygous mice exhibited
biallelic inactivation of Ink4a and Arf, whereas Ink4b was retained
in 6 of 7 MM samples tested. Expression of Nf2 and p53 was
retained in nearly all MM cultures from Ink4a(+/2), Arf(+/2), and
Ink4a;Arf(+/2) mice (Fig. 3).
Cytogenetic analyses were performed on two randomly-
selected MM cultures from each mouse model. As in the human
disease counterpart, MMs from Ink4a-, Arf-, and Ink4a;Arf-
deficient mice typically showed numerous chromosome alter-
ations. No consistent alteration was seen, although 3 of 6 tumors
had extra copies of chromosome 19, including a MM from an
Ink4a(+/2) mouse (#264), in which gain of chromosome 19 was
the only abnormality observed. MM cultures from Arf- and
Ink4a;Arf-deficient mice typically had numerous clonal structural
rearrangements (Fig. 4A). Furthermore, aCGH analysis revealed
a homozygous deletion encompassing the Cdkn2a/Arf locus
(Fig. 4B).
Discussion
Previous studies have shown that Arf(2/2)a n dInk4a(2/2)
mice are more prone to spontaneous tumors than wild-type
animals, but each less so than Ink4a;Arf(2/2) mice [8]. The in vivo
carcinogenesis studies reported here evaluated the contribution of
heterozygous mutations of Arf and Ink4a, as well as a both tumor
suppressor genes, to the induction of MM by asbestos, a well-
established cause of this malignancy. In vivo genetic models were
used to investigate the relative impact of Arf versus Ink4a
deficiency in a common genetic background. By analogy, our
findings suggest that p14(ARF), like p16(INK4A), is an important
target of 9p21 deletions in human MM. Moreover, the data
indicate that co-deletion of Arf and Ink4a can cooperate to
accelerate tumorigenesis.
In previous studies of heterozygous Arf mice, spontaneous
tumors exhibited loss of the residual wild-type Arf allele [2],
consistent with a classical two-hit tumor suppressor gene. We
found asbestos-induced MMs from heterozygous Ink4a, Arf and
Ink4a;Arf mice required biallelic inactivation of the predisposing
tumor suppressor genes, and MMs were detected faster in the
Figure 1. Accelerated asbestos-induced MM in mice deficient for Ink4a, Arf,o rInk4a;Arf. Kaplan-Meier survival curves (GraphPad Prism 5).
Mice with no tumors or with incidental tumors were censored. A log-rank test verified significant differences between wild-type and Ink4a-, Arf- and
Ink4a;Arf-deficient groups (p-value=0.0342, 0.0312, and ,0.0001, respectively).
doi:10.1371/journal.pone.0018828.g001
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suppressors is in accordance with an investigation using
conditional knockout mice [9], in which adeno-Cre-mediated
homozygous excision of Ink4a;Arf was sufficient to induce MM in
the absence of asbestos exposure.
Notably, while tumor cells from Ink4a(+/2)-deficient mice
acquired loss of Arf or p53 expression, loss of p16(Ink4a) was
observed in only 3 of 6 MMs from Arf(+/2) mice. Similarly, in
our earlier studies of Arf-deficient mice in a different (C57Bl/6)
genetic background, all 11 MMs analyzed showed loss of Arf,
although loss of p16(Ink4a) was identified in only two tumors.
Collectively, these data imply that inactivation of Arf or p53
may be crucial for MM pathogenesis, whereas inactivation of
p16(Ink4a) is not.
Since MMs analyzed here retained expression of p15Ink4b, loss
of this gene is not critical for induction of MM by asbestos. In
addition, our deletion mapping studies of human MMs revealed
that deletions of p15INK4B occur less frequently than losses of
CDKN2A/ARF and never occurred in the absence of a homozy-
gous loss in the CDKN2A/ARF locus [5].
Also similar to our earlier study of Arf-deficient mice in a
different (C57Bl/6) background, we rarely observed loss of Nf2
in MMs arising in Ink4a-, Arf-o rInk4a;Arf-deficient mice.
Inactivation of the NF2 tumor suppressor gene is postulated to
facilitate cell cycle progression and tissue invasion/metastasis
[10], and Nf2-deficient mice are predisposed to asbestos-induced
MM and contribute to its invasiveness and spreading [5,11].
However, NF2/merlin loss does not appear to be required for
development of MM in mice having this genotype and/or
background.
Lastly, we found retention of functional p53 expression in MM
cells that exhibit loss of Arf expression. Only one of the 20
asbestos-induced MMs showed loss of p53 expression (Fig. 3B),
and that single sample retained expression of Arf, consistent with
our previous work showing a reciprocal pattern of inactivation of
Tp53 in asbestos-induced MMs from Nf2(+/2) mice that had
retained expression of Arf [5,6]. Interestingly, in MM cells with
loss of Arf, the p53 pathway appeared to remain functional based
on response to DNA damage (Fig. 3C). These results from genetic
model systems suggest that Arf loss can contribute to MM
pathogenesis via p53-independent pathway(s), as previously noted
in human MM cells [12], and that an intact p53 pathway remains
a potential target for the treatment of this highly aggressive,
chemo-resistant malignancy.
In summary, this is the first report directly assessing the relative
importance of Ink4a and Arf in the susceptibility to asbestos-
induced MM. Collectively, these in vivo data indicate that both
Cdkn2A/Arf gene products suppress asbestos carcinogenicity.
Furthermore, while Arf inactivation appears to be critical for
MM pathogenesis and genomic instability (Fig. 4), the inactivation
of both p16(Ink4a) and p19(Arf) cooperate to accelerate asbestos-
induced tumorigenesis. Thus, future therapeutic approaches for
MM should consider targeting pathways cooperatively regulated
by both tumor suppressor genes.
Materials and Methods
Animals and treatments
Ink4a (01XE4, FVB.129-Cdkn2a
tm2.1Rdp) [3] and Ink4a;Arf
(01XB2, FVB/N.129-Cdkn2a
tm1Rdp) [4] mice were from the Mouse
Figure 2. Representative histopathology of asbestos-induced MMs. Sections were stained with hematoxylin and eosin (H&E) or with
antibodies against mesothelin (MSN), cytokeratin (CK8), and pan-cytokeratin (Pan-CK).
doi:10.1371/journal.pone.0018828.g002
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N. Sharpless) were generated with Cre-mediated excision of the
neomycin selection cassette, similar to Ink4a mice [3]. All mice
were in a comparable genetic background [8]. Mice were
backcrossed at least two additional generations with FVB/N mice
for uniformity and genotyped as described (MMHCC and [8]).
Procedures were compliant with the NIH Guide for the Care and Use
of Laboratory Animals.
6–8 week-old mice were injected intraperitoneally every 3 weeks
with 400 mg crocidolite (UICC, SPI Supplies) (total, 3.2 mg/
mouse), or with equivalent control TiO2 particles (Aldrich) [5,6].
Mice were scored as having MM based on histological evidence
and/or if tumor cells exhibited a combination of three or more
MM markers, including mesothelin, as assessed by reverse
transcriptase-PCR (RT-PCR) and/or immunohistochemistry
(Supplemental tables in File S1, Supplemental Fig. S1). This study
was carried out in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Fox Chase
Cancer Center (protocol number: 00-26). All surgery was
performed under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering.
Immunohistochemistry
Slides of formalin-fixed, paraffin-embedded samples were
incubated with antibodies against pan-cytokeratin and cytoker-
atin 8 (Sigma) and mesothelin (Santa Cruz Biotechnology),
which were detected with biotinylated secondary antibodies.
Sections were stained with DAB and counterstained with
hematoxylin.
Primary cell cultures. Primary MM cells were isolated from
ascitic fluid and/or peritoneal lavage, as described [5]. All primary
cell cultures used for the molecular analyses were from passages
#6. PCR analysis was conducted on all cultures that expressed
mesothelial markers, and immunoblot analysis was performed on a
random set of cultures to validate the PCR results. To test for p53,
sub-confluent mouse MM cells (.passage 6) were treated with
Etoposide (100 mM) or UV irradiation (80 J/m
2) and harvested
24 hours post-treatment for immunoblotting.
PCR
RT-PCR was used to evaluate tumor cells for expression of E-
cadherin, N-cadherin, cytokeratin 18 and cytokeratin 19 [5].
ControlGapdhwasusedtoassesstemplateintegrity[6].RT-PCRfor
mesothelin used primers 59-ATCAAGACATTCCTGGGTGGG-
39 and 59-CGGTTAAAGCTGGGAGCAGAG-39. Oligonucleo-
tides for genomic and RT-PCR of Ink4a, Ink4b, Nf2 and p53 were as
described [5,6]. Primers for p19(Arf) exon 1b were based on
National Center of Biotechnology Information (NCBI) sequences.
Immunoblotting
Immunoblots were prepared with 15–30 mg of protein/sample,
as described [5,6]. Antibodies included anti-Arf (Abcam), anti-p53
(NCL-p53-505, Novocastra), and anti-Ink4a (M-156), -Nf2 (H-
260), and -b-actin (I-19) (Santa Cruz).
Figure 3. Biallelic inactivation of predisposing Ink4a and Arf tumor suppressor genes in MM. A, Composite depicting RT-PCR for Arf exon
1b, Ink4a exon 1a, Ink4b, Nf2 and Tp53 from primary MM cells (passage #5). B, Immunoblotting of MM cells. Note that Arf was lost in nearly all tumors,
with p53 expression being absent in the only tumor (#200) retaining Arf expression. Two bands were observed in the Nf2 immunoblot (panel 3). An
asterisk beside the lower band depicts Nf2, with a non-specific band accounting for the upper signal. Actin was a loading control. C, Immunoblot of
MM cells treated with Etoposide (100 mM) or UV irradiation (80 J/m
2) 24 hours post-treatment.
doi:10.1371/journal.pone.0018828.g003
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Preparation of metaphases and G-banding were performed as
reported [13]. Guidelines for karyotypic designations of mouse
metaphase chromosomes are found at http://www.pathology.wash
ington.edu/research/cytopages/idiograms/mouse/. Metaphase pre-
parations were hybridized using a 21Xmouse mFISH kit (MetaSys-
tems). Image capturing/processing utilized a Zeiss AxioImager Z2
fluorescence microscope, with single band pass filters (Chroma
Technology) appropriate for each fluorochrome and an Isis/mFISH
image analysis system (MetaSystems).
Array-CGH
Genomic DNA was isolated from primary MM cell cultures
at passages #6. Agilent 244K Genomic DNA Arrays and
scanner were used for DNA copy number analysis. Data were
extracted using Feature Extraction Software, and output was
imported into CGH Analytics for DNA Copy Number Analysis
(Agilent).
Supporting Information
Figure S1 Immunohistochemical staining of a MM tumor with
anti-mesothelin (MSN) or anti-MSN plus blocking peptide to show
specificity of staining.
(TIF)
Figure S2 Retention of mutant Arf allele in MMs from Arf (+/2)
mice. A, Abnormally large RT-PCR product amplified with Arf-
specific primers for exon 1b. Samples are from MM cells of five Arf
Figure 4. Chromosomal analyses of MM cells from an Arf-deficient mouse. A, mFISH revealed one or more copies of 1;15, 1;18, 2;13, 5;6, and
6;14 rearrangements; der(6) composed of (from centromere to telomere) segments of chromosomes 6, 4, 6, and 4; deletion of chromosome 14; and
trisomies of chromosomes 8, 10, 17 and 19. B, aCGH analysis showed gains of chromosomes 8, 10, 13, 17, 18, and 19; and deletions of two regions of
chromosome 4, one of which (lower) represents a homozygous deletion encompassing the Cdkn2a/Arf locus embedded within a hemizygous
deletion.
doi:10.1371/journal.pone.0018828.g004
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fibroblasts. B, Sequencing of PCR products revealed an 84-bp
insertion (grey italicized letters) in the mutated Arf allele (Mu.)
replacing an AG (underlined) in the wild-type allele (Wt.). The
insertion generates a predicted stop codon (marked in black),
which would result in unsuccessful translation of the p19(Arf)
protein.
(TIF)
File S1 MM Markers for primary cell cultures derived from
asbestos-treated mice.
(DOC)
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